Ajaya Kumar Rout | Biotechnology | Best Researcher Award

Posted on by ScienceFather

Dr. Ajaya Kumar Rout: Biotechnology: Best Researcher Award

🔬 Dr. Ajaya Kumar Rout- Pioneering Bioinformatics Explorer 🧬 Dedicated to unraveling the mysteries of microbial ecosystems, Dr. Ajaya Kumar Rout is a dynamic researcher specializing in Metagenomics, Meta-Transcriptomics, Genomics, and more. Currently an ICMR-Senior Research Fellow at Rani Lakshmi Bai Central Agricultural University, Dr. Ajaya Kumar Rout holds a Ph.D. in Biosciences & Biotechnology. Their eight years of research spans prestigious roles, garnering accolades like the ICMR-SRF and Young Scientist Award. Proficient in diverse bioinformatics tools and databases, Dr. Ajaya Kumar Rout is shaping the future of genomics. An engaging speaker and prolific writer, Dr. Ajaya Kumar Rout serves as an Editorial Board Member and Reviewer for renowned journals. 🌐🧑‍🔬🔍

🔬 Dr. Ajaya Kumar Rout, Ph.D.

Dr. Ajaya Kumar Rout is a dedicated researcher in the field of bioinformatics and genomics, with a focus on metagenomics, meta-transcriptomics, and population genetics. Currently serving as an ICMR-Senior Research Fellow at Rani Lakshmi Bai Central Agricultural University, Jhansi, Uttar Pradesh, Dr. Rout’s expertise lies in unraveling microbial communities and their functions in various ecosystems.

🎓 Academic Background:

Ph.D. in Biosciences & Biotechnology, Fakir Mohan University, Odisha (Thesis: “Metagenomic study in sediments of river Ganga to unravel microbiome and their putative function”). M.Sc. in Bioinformatics, Odisha University of Agriculture and Technology. B.Sc. with Distinction, Utkal University.

🏆 Awards and Recognitions:

Best Oral Presentation Award at a national conference on “Changing course in Global Environment: Challenges and Solutions.” ICMR-Senior Research Fellow and Young Scientist Award for outstanding contributions in Fisheries and Life Sciences. Best Research Scholar Award at ICAR-Central Inland Fisheries Research Institute.

📚 Research Experience (8 Years):

Current role as ICMR-Senior Research Fellow at Rani Lakshmi Bai Central Agricultural University. Previous roles include Young Professional-II at ICAR-Central Inland Fisheries Research Institute, contributing to projects on bioinformatics, computational biology, and fisheries.

🧰 Expertise in Tools and Techniques:

Proficient in bioinformatics tools like CLC Genomics Workbench, MG-RAST, MEGAN, GROMACS, and others. Expertise in next-generation sequence data analysis, phylogenetics, comparative genomics, molecular docking, and structure-based drug design.

🌐 Conference Presentations:

Presented at international conferences on topics such as sediment metagenomics, functional gene annotation, and structural insights into GTP binding mechanisms. Received awards for best oral and poster presentations.

👨‍🏫 Teaching and Training:

Served as a resource person in workshops and delivered invited lectures to postgraduate students on bioinformatics.

👨‍🔬 Reviewer for International Journals:

Contributed as a reviewer for journals including Journal of Biomolecular Structure and Dynamics, Frontiers in Genetics, and Journal of Molecular Graphics and Modelling.

👨‍💻 Technical Skills:

Operating systems: Windows, Ubuntu, Linux Mint. Languages: C, C++, PHP. Database: MySQL. Web Technology: HTML.

Professional Profiles:

The impact of her research is evident in citation metrics and indices from Google Scholar:

  • Cited by: All – 409.
  • Citations – 281.
  • h-index – 11.
  • Documents – 37.

A prolific researcher making meaningful contributions to the academic world!

👨‍🔬 Research Focus:

Dr. Ajaya Kumar Rout is a distinguished researcher with a multifaceted research focus. His work spans metagenomics, reverse vaccinology, and immunoinformatics. His groundbreaking studies include the identification of potential MHC Class-II-restricted epitopes from Leishmania donovani antigens, contributing significantly to the understanding of CD4+ T cell responses in leishmaniasis (Cited by: 68, Year: 2017). In the realm of metagenomics, Dr. Rout has delved into the microbial diversity of river sediments, unveiling the bioremediation potential of bacterial and fungal communities (Cited by: 41, Year: 2020). His work extends to antibiotic resistance gene analysis and beneficial microbiome exploration in river ecosystems (Cited by: 35 and 27, Years: 2020).

Publications Top Note:

 

Prof. Funan Liu | Nanobiotechnology

Posted on by ScienceFather
Prof. Funan Liu: Oncolytic Virus

Congratulations, Prof. Funan Liu, on winning the esteemed Best Researcher Award from ScienceFather! Congratulations on reaching this significant milestone in your journey. Over the past year, you’ve undoubtedly achieved incredible feats and contributed immensely to your field. Here’s to many more years of success, innovation, and fulfillment in your endeavors. Wishing you continued growth, prosperity, and joy in the years to come. Keep shining and making a difference in the world!

Dr. Funan Liu is a distinguished medical professional, serving as a Professor, Chief Physician, and Doctoral Supervisor. Recognized as a key figure in healthcare, he holds prestigious positions as a Youth Top Talent under Liaoning Province’s ‘Revitalize Liaoning Talent Program’ and China Medical University’s Youth Top Talent. Additionally, he is a candidate in the ‘Hundred Thousand Ten Thousand Talent Project’ at the Thousand-Level. Dr. Liu serves as the Chief of the Phase I Clinical Trial Center at the First Affiliated Hospital of China Medical University. His expertise and leadership contribute significantly to advancing medical research and clinical trials, making him a prominent figure in the field.

Major academic positions:  

As the Deputy Director of the Gastric Cancer Committee for the Chinese Society for the Promotion of Health Science and Technology, Dr. Funan Liu plays a pivotal role in advancing gastric cancer research and awareness. He holds several leadership positions, including Vice Chairman of the 10th Committee of the Surgical Branch in the Liaoning Medical Association, and Standing Committee Member of various prestigious organizations, such as the Integrative Oncology Branch of the Chinese Anti-Cancer Association. Dr. Liu is actively involved in committees related to esophageal cancer, tumor prevention and control, oncology, and colorectal cancer. His extensive engagement underscores his commitment to multidisciplinary collaboration and advancing cancer care in various capacities within medical associations and committees.

Undertaken projects:

Dr. Funan Liu, a prominent researcher and medical professional, has spearheaded numerous groundbreaking projects in the realm of oncology. As a principal investigator, he led two National Key R&D Program research initiatives, focusing on clinical trials and therapeutic mechanisms of novel oncolytic virus cancer treatments, and the clinical evaluation of an in vitro tumor cell drug sensitivity technology system. Simultaneously, Dr. Liu undertook two National Natural Science Foundation of China general projects, investigating pH-sensitive liposome-hybrid red blood cell membrane-coated oncolytic virus intravenous delivery technology and the role of FN1 3’UTR as a new ceRNA in gastric cancer. His comprehensive expertise extends to projects funded by Liaoning Province and the CSCO-Merck Serono Cancer Research Fund, solidifying his impactful contributions to advancing cancer research and treatment.

Hosted and participated in clinical research:

This extensive portfolio of clinical trials reflects a commitment to advancing medical science and improving patient outcomes across various oncological fronts. Driven by cutting-edge research, these trials span from Phase I to Phase III, covering a spectrum of investigational therapies for different types of advanced solid tumors. The studies explore innovative approaches such as immunotherapy combinations, targeted therapies, and novel agents, aiming to enhance treatment efficacy and patient survival. From evaluating the safety, tolerability, and pharmacokinetics of promising compounds like TIRAGOLUMAB and DN015089 to studying the potential benefits of combining checkpoint inhibitors with chemotherapy in gastric cancer (HLX10 trial), these trials address critical gaps in current cancer care.

The diversity of trials encompasses indications like breast cancer, colorectal cancer, gastric cancer, and more, reflecting a comprehensive strategy to combat a range of malignancies. The focus on specific genetic mutations, such as EGFR in cholangiocarcinoma and bladder cancer (AL8326 trial), underscores the importance of personalized medicine in tailoring treatments to individual patient profiles. Additionally, the exploration of novel agents like BC004 injection and TJ033721 reveals a dedication to identifying and developing innovative therapeutic modalities.

These studies not only aim to expand the armamentarium of available treatments but also contribute valuable insights to the evolving landscape of cancer research. By pushing the boundaries of scientific understanding, these clinical trials under the leadership of Dr. Funan Liu hold great promise in shaping the future of oncology and, ultimately, improving the lives of patients grappling with advanced solid tumors.

Professional Profiles:

The impact of her research is evident in citation metrics and indices from Google Scholar:

  • Cited by: All – 1,206.
  • Citations – 1,070.
  • h-index – 22.
  • Documents – 55.

A prolific researcher making meaningful contributions to the academic world!

Publications Top Note:
  1. Engineered bacterial outer membrane vesicles encapsulating oncolytic adenoviruses enhance the efficacy of cancer virotherapy by augmenting tumor cell autophagy
    • Published in Nature Communications in 2023 with 6 citations.
  2. Virus-Protein Corona Replacement Strategy to Improve the Antitumor Efficacy of Intravenously Injected Oncolytic Adenovirus
    • Published in ACS Nano in 2023 with 0 citations.
  3. Antigen-capturing oncolytic adenoviruses along with IDO blockade for improved tumor immunotherapy
  4. Inhibition of Tumor Metastasis by Liquid-Nitrogen-Shocked Tumor Cells with Oncolytic Viruses Infection
    • Published in Advanced Materials in 2023 with 4 citations.
  5. Oncolytic Virus-Driven Biotherapies from Bench to Bedside
    • Published in Small in 2023 with 2 citations.
  6. Self-assembled short peptides: Recent advances and strategies for potential pharmaceutical applications
    • Published in Materials Today in 2023 with 3 citations.
  7. Erythrocyte-Leveraged Oncolytic Virotherapy (ELeOVt): Oncolytic Virus Assembly on Erythrocyte Surface to Combat Pulmonary Metastasis and Alleviate Side Effects
    • Published in Advanced Science in 2023 with 0 citations.
  8. FN1 mRNA 3′-UTR supersedes traditional fibronectin 1 in facilitating the invasion and metastasis of gastric cancer through the FN1 3′-UTR-let-7i-5p-THBS1 axis
    • Published in Theranostics in 2023 with 0 citations.
  9. Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis
    • Published in Frontiers in Pharmacology in 2023 with 2 citations.
  10. Drug conjugate-based anticancer therapy – Current status and perspectives
    • Published in Cancer Letters in 2023 with 17 citations.

 

Nanobio Innovation Recognition

Posted on by ScienceFather

Introduction of Nanobio Innovation Recognition

Welcome to the forefront of biological innovation at the Nanobio Innovation Recognition. This distinguished award celebrates trailblazers who have significantly contributed to the convergence of nanotechnology and the life sciences, driving breakthroughs in biomedicine, diagnostics, and beyond.

Award Eligibility:

The Nanobio Innovation Recognition is open to researchers, scientists, and innovators globally. There are no age limits, and applicants should demonstrate a commitment to advancing the field of nanobiotechnology through their pioneering work.

Qualification and Publications:

Applicants should hold a minimum of a bachelor’s degree in a relevant field and showcase their commitment through impactful publications, patents, or innovations that highlight their expertise in the intersection of nanotechnology and the life sciences.

Recurrence:

This award is an annual recognition, providing a recurring platform for innovators to showcase their ongoing contributions to the dynamic field of nanobio innovation.

Evaluation Criteria:

Candidates will be evaluated based on the impact, originality, and transformative nature of their work in nanobiotechnology. Judges will assess the significance of their contributions to biomedicine, diagnostics, and other areas where nanotechnology intersects with the life sciences.

Submission Guidelines:

Detailed submission guidelines can be found on our official website. Applicants are required to submit a comprehensive biography, an abstract outlining their nanobio innovations, and supporting files that illustrate the impact and potential of their groundbreaking work.

Recognition:

Recipients of the Nanobio Innovation Recognition will receive global recognition for their outstanding contributions, including features in leading scientific publications and invitations to exclusive events in the nanobiotechnology community.

Community Impact:

Beyond personal recognition, the award aims to amplify the community impact of nanobio innovators by fostering collaboration and knowledge exchange among researchers, scientists, and industry leaders.

Biography, Abstract, and Supporting Files:

Applicants are encouraged to provide a detailed biography showcasing their journey in nanobio innovation. The abstract should succinctly summarize key innovations and their impact on biomedicine, diagnostics, or other relevant fields. Supporting files, such as research papers, patent documents, or testimonials, can be submitted to enhance the understanding of their contributions.